Related references
Note: Only part of the references are listed.Busulfan in Infant to Adult Hematopoietic Cell Transplant Recipients: A Population Pharmacokinetic Model for Initial and Bayesian Dose Personalization
Jeannine S. McCune et al.
CLINICAL CANCER RESEARCH (2014)
Evaluating the physiological reserves of older patients with cancer: The value of potential biomarkers of aging?
Athanasios G. Pallis et al.
JOURNAL OF GERIATRIC ONCOLOGY (2014)
Accurate Targeting of Daily Intravenous Busulfan with 8-Hour Blood Sampling in Hospitalized Adult Hematopoietic Cell Transplant Recipients
Rosa F. Yeh et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2012)
Body Weight-Dependent Pharmacokinetics of Busulfan in Paediatric Haematopoietic Stem Cell Transplantation Patients Towards Individualized Dosing
Imke H. Bartelink et al.
CLINICAL PHARMACOKINETICS (2012)
Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma as part of the HR-NBL-1/SIOPEN trial
G. J. Veal et al.
EUROPEAN JOURNAL OF CANCER (2012)
Myeloablative Reduced-Toxicity i.v. Busulfan-Fludarabine and Allogeneic Hematopoietic Stem Cell Transplant for Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome in the Sixth through Eighth Decades of Life
Gheath Alatrash et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2011)
Linearity and Stability of Intravenous Busulfan Pharmacokinetics and the Role of Glutathione in Busulfan Elimination
Shlomo Almog et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2011)
Population Pharmacokinetics of Busulfan in Children: Increased Evidence for Body Surface Area and Allometric Body Weight Dosing of Busulfan in Children
Mirjam N. Trame et al.
CLINICAL CANCER RESEARCH (2011)
Acetaminophen Metabolism After Major Surgery: A Greater Challenge With Increasing Age
G. Pickering et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Predicting Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter Study
Arti Hurria et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808
Jonathan E. Kolitz et al.
BLOOD (2010)
Autologous SCT with a dose-reduced BU and CY regimen in older patients with non-Hodgkin's lymphoma
R. Z. Yusuf et al.
BONE MARROW TRANSPLANTATION (2009)
Busulfan in hematopoietic stem cell transplant setting
Jeannine S. McCune et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2009)
Reduced Intensity Conditioning Compared With Myeloablative Conditioning Using Unrelated Donor Transplants in Patients With Acute Myeloid Leukemia
Olle Ringden et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen
Michelle Geddes et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2008)
Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4
Shu-Feng Zhou
CURRENT DRUG METABOLISM (2008)
Randomized comparison of four-times-daily versus once-daily intravenous Busulfan in conditioning therapy for hematopoietic cell transplantation
Seong-Gil Ryu et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2007)
Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation
Tal Schechter et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2007)
Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: A comparison with an every 6-hour dosing schedule
Timothy Madden et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2007)
Phenobarbital and phenytoin increased acetaminophen hepatotoxicity due to inhibition of UDP-glucuronosyltransferases in cultured human hepatocytes
SE Kostrubsky et al.
TOXICOLOGICAL SCIENCES (2005)
Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older
H Wallen et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
I. V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients
L Nguyen et al.
BONE MARROW TRANSPLANTATION (2004)
The effect of metronidazole on busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation
C Nilsson et al.
BONE MARROW TRANSPLANTATION (2003)
Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation
JS McCune et al.
BONE MARROW TRANSPLANTATION (2002)
Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on US cancer burden
BK Edwards et al.
CANCER (2002)
Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: A phase II study
BS Andersson et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2002)
Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients
M Sandström et al.
BONE MARROW TRANSPLANTATION (2001)
Life expectancy, comorbidity and quality of life: the treatment equation in the older cancer patients
L Repetto et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2001)
Effects of phenytoin on glutathione status and oxidative stress biomarker gene mRNA levels in cultured precision human liver slices
EP Gallagher et al.
TOXICOLOGICAL SCIENCES (2001)
Plasma total glutathione concentrations in epileptic patients taking anticonvulsants
H Ono et al.
CLINICA CHIMICA ACTA (2000)
Acute safety and pharmacokinetics of intravenous busulfan when used with oval busulfan and cyclophosphamide as pretransplantation conditioning therapy: A phase I study
BS Andersson et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2000)
Share Paper
